KIT and germ cell tumor: In addition to pazopanib, two trials suggested the TKI against PDGFR, VEGFR 1–3, c‐KIT, FLT sunitinib to be of clinical benefit in patients with seminomateous or non-seminomateous germ cell tumors refractory to first line therapy.